INFI - Infinity Pharma wins buy rating from B. Riley ahead of key milestone

Marcelo Ricardo Daros/iStock via Getty Images B. Riley Securities has initiated the coverage of Infinity Pharmaceuticals ([[INFI]] -2.6%) with a buy rating highlighting the potential of the company’s immune-oncology candidate eganelisib (IPI-549), which is currently undergoing multiple cancer trials. "We view eganelisib as a de-risked candidate given its clinical profile in a host of solid tumors,” the analyst Kalpit Patel wrote with a conservative estimate of its potential utilization as second-line therapy in patients with urothelial cancer who are naïve to checkpoint inhibitors. Arguing that Infinity shares are currently undervalued, Patel says: “we would be buyers ahead of important clinical and strategic updates planned to be unfolded on July 27." Infinity shares have gained more than a third this year to well outperform the broader market as shown in the graph. However, in March, Seeking Alpha contributor Nick Cox was bullish on the stock noting among other things the prospects of

For further details see:

Infinity Pharma wins buy rating from B. Riley ahead of key milestone